Recent GNPX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2024 02:16:53 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/08/2024 10:00:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2024 02:29:40 PM
- Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting • PR Newswire (US) • 11/05/2024 02:29:00 PM
- Genprex to Participate in 2024 BIO Europe Conference • PR Newswire (US) • 10/31/2024 01:29:00 PM
- Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma • PR Newswire (US) • 10/28/2024 01:29:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 10/24/2024 04:23:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2024 01:29:33 PM
- Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive • PR Newswire (US) • 10/24/2024 01:29:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 10/22/2024 04:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/15/2024 01:29:57 PM
- Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer • PR Newswire (US) • 10/15/2024 01:29:00 PM
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics • PR Newswire (US) • 10/10/2024 01:29:00 PM
- Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting • PR Newswire (US) • 10/07/2024 01:29:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2024 09:15:33 PM
- Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes • PR Newswire (US) • 09/23/2024 01:29:00 PM
- Genprex Announces Formation of Mesothelioma Clinical Advisory Board • PR Newswire (US) • 09/19/2024 01:29:00 PM
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics • PR Newswire (US) • 09/09/2024 01:29:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/04/2024 01:30:39 PM
- Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes • PR Newswire (US) • 09/04/2024 01:29:00 PM
- Genprex to Present and Participate at Upcoming September Investor and Industry Conferences • PR Newswire (US) • 09/03/2024 12:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/16/2024 08:18:55 PM
- Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials • PR Newswire (US) • 08/15/2024 01:30:00 PM
- Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer • PR Newswire (US) • 08/14/2024 01:25:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:38:12 PM
FEATURED Are we about to see a comeback? Steakholder Foods Charges Forward with New Commitments from Multiple International Players as it Transitions to Revenue Generation • Nov 18, 2024 11:56 AM
FEATURED North Bay Resources Announces Production of Gold Concentrate and Refinery Shipment at Bishop Gold Mill, California • Nov 18, 2024 9:00 AM
One World Products Sets New Standards in Sustainability With Strategic Hemp Innovations • OWPC • Nov 18, 2024 7:54 AM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM